Home
/
Viridian Therapeutics, Inc.\DE
/
Financials
/
Quarterly
Viridian Therapeutics, Inc.\DE — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Viridian Therapeutics, Inc.\DE filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2016
Jun 30, 2016
$2.11M
Aug 15, 2016
Q1
2016
Mar 31, 2016
$2.05M
May 16, 2016
Q3
2015
Sep 30, 2015
$1.34M
Nov 13, 2015
Q2
2016
Jun 30, 2015
$1.46M
Aug 15, 2016
Q1
2016
Mar 31, 2015
$1.32M
May 16, 2016
Q3
2015
Sep 30, 2014
$1.87M
Nov 13, 2015
Q2
2015
Jun 30, 2014
$1.62M
Aug 14, 2015
Q1
2015
Mar 31, 2014
$1.48M
May 15, 2015
Q3
2014
Sep 30, 2013
$1.44M
Nov 14, 2014
Q2
2014
Jun 30, 2013
$1.24M
Aug 14, 2014
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$4.78M
May 9, 2018
Q3
2017
Sep 30, 2017
$1.63M
Nov 9, 2017
Q2
2017
Jun 30, 2017
$718.0K
Aug 11, 2017
Q1
2018
Mar 31, 2017
$462.0K
May 9, 2018
Q3
2017
Sep 30, 2016
$936.0K
Nov 9, 2017
Q2
2017
Jun 30, 2016
$1.12M
Aug 11, 2017
Q1
2017
Mar 31, 2016
$917.0K
May 11, 2017
Q3
2016
Sep 30, 2015
$501.0K
Oct 26, 2016
Q2
2016
Jun 30, 2015
$734.0K
Aug 15, 2016
Q1
2016
Mar 31, 2015
$645.0K
May 16, 2016
Q3
2015
Sep 30, 2014
$1.30M
Nov 13, 2015
Q2
2015
Jun 30, 2014
$1.27M
Aug 14, 2015
Q1
2015
Mar 31, 2014
$1.09M
May 15, 2015
Q3
2014
Sep 30, 2013
$983.6K
Nov 14, 2014
Q2
2014
Jun 30, 2013
$1.10M
Aug 14, 2014
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($34.60M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($100.74M)
Aug 6, 2025
Q3
2025
Jun 30, 2025
($100.74M)
Nov 5, 2025
Q2
2025
Mar 31, 2025
($86.91M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($86.91M)
Nov 5, 2025
Q1
2025
Mar 31, 2025
($86.91M)
May 6, 2025
Q3
2025
Sep 30, 2024
($76.69M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($64.99M)
Aug 6, 2025
Q3
2025
Jun 30, 2024
($64.99M)
Nov 5, 2025
Q1
2025
Mar 31, 2024
($48.54M)
May 6, 2025
Q2
2025
Mar 31, 2024
($48.54M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($48.54M)
Nov 5, 2025
Q3
2024
Sep 30, 2023
($47.66M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($55.06M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($55.06M)
Nov 12, 2024
Q3
2024
Mar 31, 2023
($68.15M)
Nov 12, 2024
Q1
2024
Mar 31, 2023
($68.15M)
May 8, 2024
Q2
2024
Mar 31, 2023
($68.15M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($28.91M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($29.49M)
Aug 8, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($40.01M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($106.77M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($93.87M)
May 6, 2025
Q3
2025
Sep 30, 2024
($83.48M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($72.19M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($55.90M)
May 6, 2025
Q3
2024
Sep 30, 2023
($51.22M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($59.28M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($72.47M)
May 8, 2024
Q3
2023
Sep 30, 2022
($29.79M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($29.56M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($25.89M)
May 10, 2023
Q3
2022
Sep 30, 2021
($14.13M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($18.00M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($18.52M)
May 13, 2022
Q3
2021
Sep 30, 2020
($5.41M)
Nov 5, 2021
Q2
2021
Jun 30, 2020
($6.37M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($8.00M)
May 7, 2021
Q3
2020
Sep 30, 2019
($11.23M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($8.94M)
Aug 5, 2020